Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.39 |
| ▸ | FEN1 | P39748 | 5/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25935028 | 0.90 | FFAR4 (0.49) | FFAR4ALOX5APFEN1GRM5SYK | |
| SCHEMBL25031334 | 0.90 | FFAR4 (0.47) | FFAR4ALOX5APFEN1GRM5SYK | |
| SCHEMBL25819309 | 0.84 | MAPT (0.47) | FFAR4 | |
| SCHEMBL30479064 | 0.83 | FFAR4 (0.48) | FFAR4ALOX5APFEN1GRM5 | |
| SCHEMBL25031311 | 0.83 | FFAR4 (0.48) | FFAR4ALOX5APFEN1GRM5 | |
| SCHEMBL25935256 | 0.83 | FFAR4 (0.50) | FFAR4ALOX5APFEN1GRM5HRH4 | |
| SCHEMBL25819230 | 0.82 | MAPT (0.45) | FFAR4GRM5 | |
| SCHEMBL25819203 | 0.81 | FFAR4 (0.61) | FFAR4 | |
| SCHEMBL25819437 | 0.80 | FFAR4 (0.39) | FFAR4LRRK2PDE10AHRH4 | |
| SCHEMBL25822405 | 0.80 | FFAR4 (0.60) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | FFAR4 4754/4885ALOX5AP 3637/4885FEN1 1196/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | FFAR4 4733/4885ALOX5AP 3451/4885FEN1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.